224 related articles for article (PubMed ID: 38034507)
21. Olanzapine-Samidorphan for Schizophrenia: A Systematic Review and Meta-Analysis.
Gupta D; Singh A
Indian J Psychol Med; 2024 Jan; 46(1):14-23. PubMed ID: 38524957
[TBL] [Abstract][Full Text] [Related]
22. Spectrofluorimetric first derivative synchronous approach for determination of olanzapine and samidorphan used for treatment of schizophrenia in pharmaceutical formulations and human plasma.
Salem H; Samir E; Mazen DZ; Madian H; Elkhateeb AE; Elaraby M; Rasekh MI; Gamal A
Spectrochim Acta A Mol Biomol Spectrosc; 2022 Jun; 274():121105. PubMed ID: 35272122
[TBL] [Abstract][Full Text] [Related]
23. Physiologically-Based Pharmacokinetic Modeling for Predicting Drug Interactions of a Combination of Olanzapine and Samidorphan.
Sun L; von Moltke L; Rowland Yeo K
CPT Pharmacometrics Syst Pharmacol; 2020 Feb; 9(2):106-114. PubMed ID: 31919994
[TBL] [Abstract][Full Text] [Related]
24. Opioid antagonism mitigates antipsychotic-associated weight gain: focus on olanzapine.
McIntyre RS; Citrome L; Cummings H; Todtenkopf MS; Tan LA; White M; Akerman S
CNS Spectr; 2023 Jun; 28(3):288-299. PubMed ID: 35236531
[TBL] [Abstract][Full Text] [Related]
25. Olanzapine/Samidorphan in Young Adults With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder Who Are Early in Their Illness: Results of the Randomized, Controlled ENLIGHTEN-Early Study.
Kahn RS; Kane JM; Correll CU; Arevalo C; Simmons A; Graham C; Yagoda S; Hu B; McDonnell D
J Clin Psychiatry; 2023 Mar; 84(3):. PubMed ID: 36946605
[No Abstract] [Full Text] [Related]
26. A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers.
Silverman BL; Martin W; Memisoglu A; DiPetrillo L; Correll CU; Kane JM
Schizophr Res; 2018 May; 195():245-251. PubMed ID: 29158012
[TBL] [Abstract][Full Text] [Related]
27. Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study.
Yagoda S; Graham C; Simmons A; Arevalo C; Jiang Y; McDonnell D
CNS Spectr; 2021 Aug; 26(4):383-392. PubMed ID: 32393412
[TBL] [Abstract][Full Text] [Related]
28. Application of Physiologically Based Pharmacokinetic Modeling to Predict the Effect of Renal Impairment on the Pharmacokinetics of Olanzapine and Samidorphan Given in Combination.
Sun L; von Moltke L; Rowland Yeo K
Clin Pharmacokinet; 2021 May; 60(5):637-647. PubMed ID: 33313995
[TBL] [Abstract][Full Text] [Related]
29. [Antipsychotics in bipolar disorders].
Vacheron-Trystram MN; Braitman A; Cheref S; Auffray L
Encephale; 2004; 30(5):417-24. PubMed ID: 15627046
[TBL] [Abstract][Full Text] [Related]
30. Combination of Olanzapine and Samidorphan Has No Clinically Significant Effect on the Pharmacokinetics of Lithium or Valproate.
Sun L; Yagoda S; Yao B; Graham C; von Moltke L
Clin Drug Investig; 2020 Jan; 40(1):55-64. PubMed ID: 31584140
[TBL] [Abstract][Full Text] [Related]
31. Olanzapine/samidorphan combination consistently mitigates weight gain across various subgroups of patients.
Meyer JM; Simmons A; Jiang Y; Graham C; Yagoda S; McDonnell D
CNS Spectr; 2022 Oct; ():1-4. PubMed ID: 36226902
[TBL] [Abstract][Full Text] [Related]
32. A phase 3, multicenter study to assess the 1-year safety and tolerability of a combination of olanzapine and samidorphan in patients with schizophrenia: Results from the ENLIGHTEN-2 long-term extension.
Kahn RS; Silverman BL; DiPetrillo L; Graham C; Jiang Y; Yin J; Simmons A; Bhupathi V; Yu B; Yagoda S; Hopkinson C; McDonnell D
Schizophr Res; 2021 Jun; 232():45-53. PubMed ID: 34015555
[TBL] [Abstract][Full Text] [Related]
33. Using physiologically-based pharmacokinetic modeling for predicting the effects of hepatic impairment on the pharmacokinetics of olanzapine and samidorphan given as a combination tablet.
Sun L; Barter Z; von Moltke L; Rowland Yeo K
CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1071-1080. PubMed ID: 34185436
[TBL] [Abstract][Full Text] [Related]
34. Opioid antagonists to prevent olanzapine-induced weight gain: A systematic review.
Laguado SA; Saklad SR
Ment Health Clin; 2022 Aug; 12(4):254-262. PubMed ID: 36071739
[TBL] [Abstract][Full Text] [Related]
35. Olanzapine Plus Samidorphan in Subjects with Schizophrenia and Comorbid Alcohol Use Disorder: Rationale and Design for a Phase II, Double-blind, Randomized Study.
Citrome L; O'Malley SS; McDonnell D; Jiang Y; Simmons AC; Berry MP; Dipetrillo LE
Innov Clin Neurosci; 2019 May; 16(5-6):15-21. PubMed ID: 31440397
[No Abstract] [Full Text] [Related]
36. Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study.
Potkin SG; Kunovac J; Silverman BL; Simmons A; Jiang Y; DiPetrillo L; McDonnell D
J Clin Psychiatry; 2020 Mar; 81(2):. PubMed ID: 32141723
[TBL] [Abstract][Full Text] [Related]
37. A Review of Samidorphan: A Novel Opioid Antagonist.
Chaudhary AMD; Khan MF; Dhillon SS; Naveed S
Cureus; 2019 Jul; 11(7):e5139. PubMed ID: 31523568
[TBL] [Abstract][Full Text] [Related]
38. New discoveries for an old drug: a review of recent olanzapine research.
Meftah AM; Deckler E; Citrome L; Kantrowitz JT
Postgrad Med; 2020 Jan; 132(1):80-90. PubMed ID: 31813311
[No Abstract] [Full Text] [Related]
39. Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study.
Correll CU; Stein E; Graham C; DiPetrillo L; Akerman S; Stanford AD; Jiang Y; Yagoda S; McDonnell D; Hopkinson C
Schizophr Bull; 2023 Mar; 49(2):454-463. PubMed ID: 36305696
[TBL] [Abstract][Full Text] [Related]
40. How Much of an Advance Is the Addition of Samidorphan to Olanzapine?
Buchanan RW
Am J Psychiatry; 2020 Dec; 177(12):1113-1114. PubMed ID: 33256454
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
